Frederic R Santer
Overview
Explore the profile of Frederic R Santer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
813
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torzsok P, Santer F, Kunz Y, van Creij N, Tymoszuk P, Klinglmair G, et al.
Basic Clin Androl
. 2025 Feb;
35(1):8.
PMID: 40011822
Background: Gonadotropin dysregulation seems to play a potential role in the carcinogenesis of testicular germ cell tumor (TGCT). The aim of this study was to explore the expression of specific...
2.
Fracassi G, Lorenzin F, Orlando F, Gioia U, DAmato G, Casaramona A, et al.
J Clin Invest
. 2024 Dec;
135(4).
PMID: 39718835
PARP inhibitors (PARPi) have received regulatory approval for the treatment of several tumors, including prostate cancer (PCa), and demonstrate remarkable results in the treatment of castration-resistant prostate cancer (CRPC) patients...
3.
Van Goubergen J, Perina M, Handle F, Morales E, Kremer A, Schmidt O, et al.
Mol Oncol
. 2024 Sep;
19(2):496-518.
PMID: 39258426
In advanced prostate cancer (PC), in particular after acquisition of resistance to androgen receptor (AR) signaling inhibitors (ARSI), upregulation of AR splice variants compromises endocrine therapy efficiency. Androgen receptor splice...
4.
Torzsok P, Van Goubergen J, Pichler M, Pichler R, Santer F
Nutrients
. 2023 May;
15(10).
PMID: 37242266
Isochromosome 12p (iChr12p) is typical in almost all invasive testicular cancers. Increased copy number of genes on 12p is associated with the development of a clinically manifest tumor; however, the...
5.
Furlan T, Kirchmair A, Sampson N, Puhr M, Gruber M, Trajanoski Z, et al.
Am J Pathol
. 2021 Mar;
191(6):1094-1107.
PMID: 33705753
Patients with advanced prostate cancer are frequently treated with the antiandrogen enzalutamide. However, resistance eventually develops in virtually all patients, and various mechanisms have been associated with this process. The...
6.
Gruber M, Ferrone L, Puhr M, Santer F, Furlan T, Eder I, et al.
Endocr Relat Cancer
. 2020 Jan;
27(3):187-198.
PMID: 31951590
Administration of the microtubule inhibitor docetaxel is a common treatment for metastatic castration-resistant prostate cancer (mCRPC) and results in prolonged patient overall survival. Usually, after a short period of time...
7.
Handle F, Puhr M, Schaefer G, Lorito N, Hoefer J, Gruber M, et al.
Mol Cancer Ther
. 2018 Sep;
17(12):2722-2731.
PMID: 30254184
IL6/STAT3 signaling is associated with endocrine therapy resistance in prostate cancer, but therapies targeting this pathway in prostate cancer were unsuccessful in clinical trials so far. The mechanistic explanation for...
8.
Navone N, van Weerden W, Vessella R, Williams E, Wang Y, Isaacs J, et al.
Prostate
. 2018 Aug;
78(16):1262-1282.
PMID: 30073676
Background: While it has been challenging to establish prostate cancer patient-derived xenografts (PDXs), with a take rate of 10-40% and long latency time, multiple groups throughout the world have developed...
9.
Guggenberger F, van de Werken H, Erb H, Cappellano G, Trattnig K, Handle F, et al.
Eur Urol
. 2018 Jun;
74(6):847-849.
PMID: 29914715
No abstract available.
10.
Culig Z, Santer F
Methods Mol Biol
. 2018 May;
1786:259-262.
PMID: 29786798
High expression of several androgen receptor coactivators is frequently reported in prostate cancer. Coactivators such as p300/CBP are involved in modulation of androgen receptor activity by increasing the effects of...